Keywords: efficacy, dupont, merck, dmp, investigational, non-nucleoside, reverse
Efficacy With DuPont Merck's DMP 266
Article | 03 February 1997
DuPont Merck's investigational non-nucleoside reverse transcriptaseinhibitor DMP 266 has demonstrated significant viral load reduction and CD4 cell recovery when given in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
